AI-supported diagnostics and prognosis platform for assessing the risk of (intestinal) cancer patients
CompanyOwkin, Boston, USA
To classify and assess the risk of colorectal cancer, the company Owkin has developed the AI-supported diagnostic tool MSIntuit® CRC. The method enables digital pre-screening of surgically removed tumor tissue samples for the presence (or absence) of genetic microsatellite instability (MSI). Approximately 15% of the entire colon cancer population has MSI, of which approximately 20% are affected by hereditary Lynch syndrome (HNPCC), which is why MSI is considered a valuable biomarker for the diagnosis of colorectal cancer (CRC) and for predicting the course of the disease. So far it has been shown that the AI predictions have a sensitivity of 95%. MSI pre-screening also plays an important role in determining the treatment decision. Colorectal cancer patients with MSI show better prognoses and do not benefit from chemotherapy in stage II. In addition, the screening platform may also be relevant for other tumor diseases, as therapy with immune checkpoint inhibitors (ICI) is particularly suitable for MSI patients (regardless of the type of cancer). Approved or recommended MSI screening technologies currently used by Owkin include MMR-IHC staining, MSI-PCR testing and next-generation sequencing (NGS). In summary, the MSIntuit® CRC test procedure can help to predict the risk and progression of (intestinal) cancer in order to make an appropriate therapy selection for the patient at an early stage and help to identify familial risks.
MSIntuit® CRC. Optimize MSI testing for colorectal cancer.
www.owkin.com
Added on: 01-25-2024
[1] https://www.owkin.com/msintuit-crc
